A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Clinical trial NCT01320020 · TERMINATED
Trial details
- NCT number
- NCT01320020
- Sponsor
- Neovii Biotech
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2013-03-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.